Poor
Not Aligned
Patient Risk:
Moderate
Summary
The provided FDA label excerpts do not include statements about cruciferous vegetables, soy products/isoflavones, grapefruit/naringenin, or any nutrition/food interaction warnings. Most food-interaction claims are therefore unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that belongs to the class of HMG-CoA reductase inhibitors.
Not supported or contradicted by the provided label excerpts.
Lipitor works by reducing the production of cholesterol in the liver.
Not supported or contradicted by the provided label excerpts.
Lipitor lowers the amount of cholesterol in the bloodstream.
Not supported or contradicted by the provided label excerpts.
Unsupported Statements
Cruciferous vegetables (e.g., broccoli, cauliflower, kale) contain isothiocyanates that may inhibit the activity of certain enzymes in the liver, which may affect the metabolism of Lipitor.
No nutrition/vegetable interaction information is present in the supplied label excerpts.
The impact of the interaction between cruciferous vegetables and Lipitor is likely to be minimal.
No food-interaction magnitude/likelihood statements are present in the supplied label excerpts.
Soy products (e.g., tofu, soy milk) contain isoflavones that may interact with Lipitor.
No soy/isoflavone interaction information is present in the supplied label excerpts.
Isoflavones can bind to estrogen receptors in the body, which may affect the way Lipitor is metabolized.
No estrogen-receptor/isoflavone mechanism or metabolism statements are present in the supplied label excerpts.
The FDA has deemed soy products to be safe for consumption while taking Lipitor.
No FDA-deeming/approval statement about soy safety during Lipitor use is present in the supplied label excerpts.
Grapefruit and grapefruit juice can interact with Lipitor.
No grapefruit/juice interaction warning is present in the supplied label excerpts.
Compounds in grapefruit, such as naringenin, can inhibit the activity of certain enzymes in the liver, which may affect the metabolism of Lipitor.
No grapefruit/naringenin/enzymatic mechanism statements are present in the supplied label excerpts.
The FDA has not issued a warning about grapefruit and Lipitor.
Whether the FDA issued/not issued a warning about grapefruit is not addressed in the supplied label excerpts.
The risk of interaction between grapefruit and Lipitor is considered to be low.
No interaction-risk categorization is present in the supplied label excerpts.
Other vegetables (e.g., carrots, sweet potatoes, and squash) do not appear to interact with Lipitor.
No vegetable-specific interaction statements are present in the supplied label excerpts.
Other vegetables are generally considered safe to consume while taking Lipitor.
No general dietary safety statements are present in the supplied label excerpts.
The risk of vegetable interaction with Lipitor is generally considered to be low.
No dietary-interaction risk guidance is present in the supplied label excerpts.
Most vegetables are safe to consume while taking Lipitor.
No dietary guidance is present in the supplied label excerpts.
Cruciferous vegetables are generally considered safe to consume while taking Lipitor.
No cruciferous-vegetable safety statements are present in the supplied label excerpts.
Eating soy products is unlikely to affect the way Lipitor works.
No soy interaction likelihood statements are present in the supplied label excerpts.
Grapefruit is generally considered safe to consume while taking Lipitor.
No grapefruit safety guidance is present in the supplied label excerpts.
No other vegetables are recommended to be avoided while taking Lipitor.
No list of avoided foods is present in the supplied label excerpts.
Carrots and sweet potatoes are generally safe to consume while taking Lipitor.
No carrot/sweet-potato safety statements are present in the supplied label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No FDA-label-supported indication, dosing, or contraindication details were provided in the AI claims. For the included claims, there is no label-supported content beyond the drug/dose-mechanism generalities (which were not supported by the provided label excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The nutrition/food interaction assertions are not supported by the supplied prescribing information, including statements claiming low risk/safety. Unsupported guidance could lead to inappropriate assumptions about safety of concomitant dietary intake.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims about specific foods (cruciferous vegetables, soy/isoflavones, grapefruit/naringenin) and FDA safety/warning status are absent from the supplied Lipitor prescribing information excerpts and are therefore unsupported.
Suggested Improvement
Restrict statements to content explicitly present in the provided label excerpts; for food interaction claims, use only warnings/precautions or interaction information that appears in the label text provided.